Dr. D’Angelo on Selecting CAR T-Cell Therapy or Transplantation in DLBCL

Video

Christopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.

Christopher R. D’Angelo, MD, an assistant professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of Nebraska Medical Center, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

For some patients, there may be some concern about potential responses to salvage chemotherapy, D’Angelo says. If a patient demonstrates a mixed response with some tumor shrinkage but stability in other lesions, that may raise the question as to how durable that treatment is and how chemotherapy-sensitive the patient is, D’Angelo explains. As such, that may serve as the rationale for utilizing CAR T-cell therapy over salvage chemotherapy while trying to remain within the strict criteria for its use, D’Angelo notes.

At the same time, it is important to recognize that there is a patient population where questions remain as to how well transplant will work, as well as whether it is worth the associated toxicities if they are going to relapse. If patients are going to relapse or are chemotherapy refractory, it is difficult to begin selecting a simultaneous next-line therapy while patients are still recovering from autologous stem cell transplant, D’Angelo concludes.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
© 2025 MJH Life Sciences

All rights reserved.